Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand

Chong HY 1 , Saokaew S 2 , Dumrongprat K 3 , Permsuwan U 4 , Wu DB 1 , Sritara P 5 Show all authors , Chaiyakunapruk N 6

Affiliations 

  • 1 School of Pharmacy, Monash University Malaysia, Selangor, Malaysia
  • 2 Center of Health Outcomes Research and Therapeutic Safety (COHORTS), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand; Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
  • 3 Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue Cardiff CFJ 0 3XF Wales UK
  • 4 Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand
  • 5 Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • 6 School of Pharmacy, Monash University Malaysia, Selangor, Malaysia; Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; School of Pharmacy, University of Wisconsin, Madison, USA; School of Population Health, University of Queensland, Brisbane, Australia. Electronic address: nathorn.chaiyakunapruk@monash.edu
Thromb Res, 2014 Dec;134(6):1278-84.
PMID: 25456732 DOI: 10.1016/j.thromres.2014.10.006

Abstract

Pharmacogenetic (PGx) test is a useful tool for guiding physician on an initiation of an optimal warfarin dose. To implement of such strategy, the evidence on the economic value is needed. This study aimed to determine the cost-effectiveness of PGx-guided warfarin dosing compared with usual care (UC).

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications